Lung Cancer Therapeutics Market Analysis 2019, Research Report, Global Industry Size, Growth, In-Depth Analysis, Top Companies, Opportunities, Regional Overview by 2026

Lung cancer also called lung carcinoma is a fatal tumor, which is known for its uncontrolled growth in the lungs. As the size of the tumor increases, the ability of lungs to provide oxygen to bloodstreams decreases. The lung carcinoma is classified as, non-small cell and small cell lung cancer and originates from the epithelial cells. Lung cancer has the highest mortality rate globally, wherein major reasons behind it are excessive smoking of cigarettes and pipe along with exposure to asbestos. There are various symptoms of lung cancer including body mucus, chest pain, weight loss, and coughing. Oncologists suggest different treatment options for lung cancer including chemotherapy, immunotherapy, vaccines, and radiation therapy.

To get detailed table of content (ToC), please click – https://www.coherentmarketinsights.com/ongoing-insight/toc/702

Market Dynamics

Growing incidences of non-small cell lung cancer is expected to drive the global lung cancer therapeutics market growth

Increasing occurrence of non-small cell lung cancer is expected to propel growth of the global lung cancer therapeutics market during the forecast period. According to the World Health Organization (WHO), 2017, 1.8 million new lung cancer cases were diagnosed in 2012 globally, accounting for the leading causes of morbidity and mortality. The launch of innovative radiation therapies, premium priced drugs, and rising incidences of non-small cell lung cancer (NSCLC) are major factors driving growth of the market. Moreover, growing demand for targeted therapies is expected to boost growth of the global lung cancer therapeutics market during the forecast period. Targeted therapies block the growth by targeting cancer-specific proteins, cells, and tissues that lead to cancer survival and division, without damaging the healthy cells. They are also proved to have higher efficiency over conventional therapies like platinum-based chemotherapy, surgical resection, and radiation therapy. Increasing diagnostic facilities by the government, rise in unhealthy lifestyles, and increasing pollution due to rapid industrialization are the prominent factors driving the global lung cancer therapeutics market. The novel treatment termed targeted therapy is expected to have positive impact on the market

Tailored Information as per niche requirement:
LIMITED TIME OFFER – Hurry Up!

Get Discount For Buyers UPTO 30% OFF On Any Research Report
Apply Promo Code “CMIFIRST1000” And Get Instant Discount Of USD 1000
Buy Now this Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/702

The global lung cancer therapeutics market is segmented on the basis of therapy, distribution channel, and geography

On the basis of therapy, the global lung cancer therapeutics market is segmented into:

• Chemotherapy
• Gemzar
• Alimta
• Paraplatin
• Taxotere
• Navelbine
• Targeted therapy
• Avastin
• Tarceva
• Iressa
• Gilotrif
• Radiotherapy
• Systemic Radiotherapy
• External Beam Radiotherapy
• Internal Radiotherapy

On the basis of distribution channel, the global lung cancer therapeutics market is segmented into:

• Pharmacies
• E-commerce
• Retail Pharmacies
• Others

To understand Research Methodology, please click https://www.coherentmarketinsights.com/ongoing-insight/lung-cancer-therapeutics-market-702

Regional Insights

Higher carcinoma lung population dominates the lung cancer therapeutics market in North America

Regional segmentation of the lung cancer therapeutics market by Coherent Market Insights comprises North America, Europe, Asia-Pacific, Latin America and Middle East, and Africa. Among regions, North America holds the dominant position in the global lung cancer therapeutics market, owing to presence large number of lung cancer patients. According to the American Cancer Society estimates of 2017, around 195,000 people are suffering from NSCLC every year in the U.S. where, the number of deaths from NSCLC is recorded to be around 135,000, thus increasing the demand for lung cancer therapeutics in the region. Moreover, rising prevalence of lung cancer, increasing geriatric population, high smoking habits leading to higher carcinoma lung population are expected to drive the market growth in the region. Asia Pacific is estimated to witness a higher growth rate during the forecast period, owing to growing awareness of enhanced health care, government funding, and the presence of medical requirements for cancer therapeutics in the emerging economies of India and China.

New product launches with higher efficiency forms a major growth strategy of market players

Major players operating the global lung cancer therapeutics market are Pfizer, Celgene, F. Hofmann-La Roche, AstraZeneca, and Eli Lilly. The key players adopt various strategies such as, development of efficient drugs, acquisition and mergers, geographical expansion and major investment in research and development to maintain their position in the market. Other prominent vendors include ARIAD Pharmaceuticals, OSE Immunotherapeutics, Novartis, Bristol-Myers Squibb, and OncoGeneX.

Special Requirements?
We value your investment and offer customization as per your requirements.

Share your precise requirements @ https://www.coherentmarketinsights.com/insight/request-customization/702

Table of Content

Global Lung Cancer Therapeutics Market Research Report
Section 1: Global Lung Cancer Therapeutics Industry Overview
Section 2: Global Economic Impact on Lung Cancer Therapeutics Industry
Section 3: Global Market Competition by Industry Producers
Section 4: Global Productions, Revenue (Value), according to Regions
Section 5: Global Supplies (Production), Consumption, Export, Import, geographically
Section 6: Global Productions, Revenue (Value), Price Trend, Product Type
Section 7: Global Market Analysis, on the basis of Application
Section 8: Lung Cancer Therapeutics Market Pricing Analysis
Section 9: Market Chain, Sourcing Strategy, and Downstream Buyers
Section 10: Strategies and key policies by Distributors/Suppliers/Traders
Section 11: Key Marketing Strategy Analysis, by Market Vendors
Section 12: Market Effect Factors Analysis
Section 13: Global Lung Cancer Therapeutics Market Forecast

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website – www.coherentmarketinsights.com

Contact:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837